244 related articles for article (PubMed ID: 27552545)
1. Beneficial Effects of GH in Young Adults With Prader-Willi Syndrome: A 2-Year Crossover Trial.
Kuppens RJ; Bakker NE; Siemensma EP; Tummers-de Lind van Wijngaarden RF; Donze SH; Festen DA; van Alfen-van der Velden JA; Stijnen T; Hokken-Koelega AC
J Clin Endocrinol Metab; 2016 Nov; 101(11):4110-4116. PubMed ID: 27552545
[TBL] [Abstract][Full Text] [Related]
2. Metabolic health profile in young adults with Prader-Willi syndrome: results of a 2-year randomized, placebo-controlled, crossover GH trial.
Kuppens RJ; Bakker NE; Siemensma EP; Donze SH; Stijnen T; Hokken-Koelega AC
Clin Endocrinol (Oxf); 2017 Feb; 86(2):297-304. PubMed ID: 27689944
[TBL] [Abstract][Full Text] [Related]
3. Bone mineral density in young adults with Prader-Willi syndrome: A randomized, placebo-controlled, crossover GH trial.
Donze SH; Kuppens RJ; Bakker NE; van Alfen-van der Velden JAEM; Hokken-Koelega ACS
Clin Endocrinol (Oxf); 2018 Jun; 88(6):806-812. PubMed ID: 29418016
[TBL] [Abstract][Full Text] [Related]
4. Growth hormone therapy improves exercise capacity in adult patients with Prader-Willi syndrome.
Gondoni LA; Vismara L; Marzullo P; Vettor R; Liuzzi A; Grugni G
J Endocrinol Invest; 2008 Sep; 31(9):765-72. PubMed ID: 18997487
[TBL] [Abstract][Full Text] [Related]
5. Effect of cessation of GH treatment on cognition during transition phase in Prader-Willi syndrome: results of a 2-year crossover GH trial.
Kuppens RJ; Mahabier EF; Bakker NE; Siemensma EP; Donze SH; Hokken-Koelega AC
Orphanet J Rare Dis; 2016 Nov; 11(1):153. PubMed ID: 27852283
[TBL] [Abstract][Full Text] [Related]
6. Short-term growth hormone treatment in girls with Turner syndrome decreases fat mass and insulin sensitivity: a randomized, double-blind, placebo-controlled, crossover study.
Gravholt CH; Naeraa RW; Brixen K; Kastrup KW; Mosekilde L; Jørgensen JO; Christiansen JS
Pediatrics; 2002 Nov; 110(5):889-96. PubMed ID: 12415026
[TBL] [Abstract][Full Text] [Related]
7. Growth hormone treatment improves body composition in adults with Prader-Willi syndrome.
Höybye C; Hilding A; Jacobsson H; Thorén M
Clin Endocrinol (Oxf); 2003 May; 58(5):653-61. PubMed ID: 12699450
[TBL] [Abstract][Full Text] [Related]
8. Growth hormone treatment of adults with Prader-Willi syndrome and growth hormone deficiency improves lean body mass, fractional body fat, and serum triiodothyronine without glucose impairment: results from the United States multicenter trial.
Mogul HR; Lee PD; Whitman BY; Zipf WB; Frey M; Myers S; Cahan M; Pinyerd B; Southren AL
J Clin Endocrinol Metab; 2008 Apr; 93(4):1238-45. PubMed ID: 18211968
[TBL] [Abstract][Full Text] [Related]
9. The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a 2-year, controlled study.
Whitman BY; Myers S; Carrel A; Allen D
Pediatrics; 2002 Feb; 109(2):E35. PubMed ID: 11826245
[TBL] [Abstract][Full Text] [Related]
10. One year of growth hormone treatment in adults with Prader-Willi syndrome improves body composition: results from a randomized, placebo-controlled study.
Sode-Carlsen R; Farholt S; Rabben KF; Bollerslev J; Schreiner T; Jurik AG; Christiansen JS; Höybye C
J Clin Endocrinol Metab; 2010 Nov; 95(11):4943-50. PubMed ID: 20702523
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone treatment in adults with Prader-Willi syndrome: the Scandinavian study.
Sode-Carlsen R; Farholt S; Rabben KF; Bollerslev J; Schreiner T; Jurik AG; Christiansen JS; Höybye C
Endocrine; 2012 Apr; 41(2):191-9. PubMed ID: 22081257
[TBL] [Abstract][Full Text] [Related]
12. Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study.
Hansen TB; Gram J; Jensen PB; Kristiansen JH; Ekelund B; Christiansen JS; Pedersen FB
Clin Nephrol; 2000 Feb; 53(2):99-107. PubMed ID: 10711411
[TBL] [Abstract][Full Text] [Related]
13. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome.
Festen DA; de Lind van Wijngaarden R; van Eekelen M; Otten BJ; Wit JM; Duivenvoorden HJ; Hokken-Koelega AC
Clin Endocrinol (Oxf); 2008 Sep; 69(3):443-51. PubMed ID: 18363884
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of long-term continuous growth hormone treatment in children with Prader-Willi syndrome.
de Lind van Wijngaarden RF; Siemensma EP; Festen DA; Otten BJ; van Mil EG; Rotteveel J; Odink RJ; Bindels-de Heus GC; van Leeuwen M; Haring DA; Bocca G; Houdijk EC; Hoorweg-Nijman JJ; Vreuls RC; Jira PE; van Trotsenburg AS; Bakker B; Schroor EJ; Pilon JW; Wit JM; Drop SL; Hokken-Koelega AC
J Clin Endocrinol Metab; 2009 Nov; 94(11):4205-15. PubMed ID: 19837938
[TBL] [Abstract][Full Text] [Related]
15. Growth hormone treatment for two years is safe and effective in adults with Prader-Willi syndrome.
Sode-Carlsen R; Farholt S; Rabben KF; Bollerslev J; Schreiner T; Jurik AG; Frystyk J; Christiansen JS; Höybye C
Growth Horm IGF Res; 2011 Aug; 21(4):185-90. PubMed ID: 21664161
[TBL] [Abstract][Full Text] [Related]
16. Eight years of growth hormone treatment in children with Prader-Willi syndrome: maintaining the positive effects.
Bakker NE; Kuppens RJ; Siemensma EP; Tummers-de Lind van Wijngaarden RF; Festen DA; Bindels-de Heus GC; Bocca G; Haring DA; Hoorweg-Nijman JJ; Houdijk EC; Jira PE; Lunshof L; Odink RJ; Oostdijk W; Rotteveel J; Schroor EJ; Van Alfen AA; Van Leeuwen M; Van Pinxteren-Nagler E; Van Wieringen H; Vreuls RC; Zwaveling-Soonawala N; de Ridder MA; Hokken-Koelega AC
J Clin Endocrinol Metab; 2013 Oct; 98(10):4013-22. PubMed ID: 24001750
[TBL] [Abstract][Full Text] [Related]
17. Long-term echocardiographic and cardioscintigraphic effects of growth hormone treatment in adults with Prader-Willi syndrome.
Marzullo P; Marcassa C; Minocci A; Campini R; Eleuteri E; Gondoni LA; Aimaretti G; Sartorio A; Scacchi M; Grugni G
J Clin Endocrinol Metab; 2015 May; 100(5):2106-14. PubMed ID: 25710568
[TBL] [Abstract][Full Text] [Related]
18. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome.
Myers SE; Carrel AL; Whitman BY; Allen DB
J Pediatr; 2000 Jul; 137(1):42-9. PubMed ID: 10891820
[TBL] [Abstract][Full Text] [Related]
19. Sustained benefits of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome are dose-dependent.
Carrel AL; Myers SE; Whitman BY; Allen DB
J Pediatr Endocrinol Metab; 2001; 14(8):1097-105. PubMed ID: 11592566
[TBL] [Abstract][Full Text] [Related]
20. Visceral adipose tissue increases shortly after the cessation of GH therapy in adults with Prader-Willi syndrome.
Koizumi M; Ida S; Shoji Y; Nishimoto Y; Etani Y; Kawai M
Endocr J; 2018 Nov; 65(11):1127-1137. PubMed ID: 30185718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
